01→
Predictive drug development
GATC Health's engine reads biological, clinical, and molecular data to rank targets, model toxicity and ADME, and forecast how a candidate performs. Independently measured above 80% accuracy.
CapabilitiesOne platform
One platform
end to end
Six capabilities that carry a molecule from target selection through regulatory approval, with the prediction work done before the expensive part starts.
Platform capabilities
02→
Conditionally Active Biologics
BioAtla antibodies that stay inactive in healthy tissue and switch on in the acidic, inflamed conditions of disease. Selectivity is the whole point.
03→
Senescence programmes
Drugs that clear the inflamed senescent cells driving age-related disease in bone, kidney, heart, liver, and lung, while sparing the ones that protect tissue.
04→
Clinical trial design
Patient populations, endpoints, and protocols modelled in silico first. Trials run smaller, enrol faster, and answer the question they were designed to answer.
05→
Regulatory execution
Studies run inside the double-blind frameworks the FDA and EMA already trust, led by operators who have taken drugs through them before.
06→
Partnering and licensing
Ernst & Young values each asset at $50 million to $150 million today, with commercial potential above $1 billion. We license, partner, or sell when the data supports it.
Pipeline
Ten assets, two horizons
Two programmes enter IND-enabling and preclinical work through 2027. The rest sit behind more than 100 international patents, waiting on the data that moves them forward.
IND-enabling · 2026
Anti-aging lead
Our first senescence programme, clearing the inflamed cells behind age-related disease in bone, kidney, heart, liver, and lung.
Preclinical · 2027
Systemic longevity
A whole-body programme targeting the biology of aging itself, alongside candidates in immune disease and CNS disorders.
Ready to talk?
Investor, partner, or clinical collaborator. Tell us your interest and timeline. We respond within one business day.